David M Urech

This inventor holds 50 USPTO granted patents and 20 published patent applications, plus 4 CIPO patents and 21 EPO patents, primarily in Antibody Engineering. Top assignees: Esbatech, an Alcon Biomedical Research Unit LLC, Numab Therapeutics Ag, Novartis Ag. Active years: 2011-2026.

USPTO Granted Patents = 50 (Patent Applications = 20)

% Patents Active = 88.0

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 21 (Patent Applications = 21)

Average Co-Inventor Count = 2.4

ph-index = 8

Forward Citations = 193(Granted Patents)

Location History:

Männedorf, CH (2011 - 2018)
Mannedorf, CH (2013 - 2018)
Hombrechtikon, CH (2012 - 2024)
Jona, CH (2015 - 2024)

Company Filing History:

27 out of 36

Esbatech, an Alcon Biomedical Research Unit LLC

patents

10 out of 15

Numab Therapeutics Ag

Esbatech, an Aclon Biomedical Research Unit LLC

patent

5. 1 out of 1

Esbatech, an Alcon Biomedical Reseach Unit LLC

patent

6. 1 out of 1

Esbatech, an Alcon Biomedical Unit LLC

patent

7. 1 out of 1

Esbatech, an Alcon Boimedical Research Unit, LLC

9. 1 out of 834,411

Other

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Multispecific Antibodies

Solubility Optimization

Immunobinders

Antibody Frameworks

Humanization

CD3 Binding

VEGF Inhibition

TNF Alpha

Single Chain Antibodies

Functionalized Polypeptides

Epithelial Passage

Disease Treatment

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723101 - ANTIBODY SPECIFICALLY BINDING TO HUMAN SERUM ALBUMIN (2026-09-01),

2. 12600769 - STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF (2026-04-14),

3. 12503505 - MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF (2025-12-23),

4. 12202911 - Multispecific antibody comprising CD137 binding domain and PDL1 binding domain (2025-01-21),

5. 12098203 - Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA (2024-09-24),

6. 11879005 - Hetero-dimeric multi-specific antibody format (2024-01-23),

7. 11858981 - Humanization of rabbit antibodies using a universal antibody framework (2024-01-02),

8. 11578123 - Stable and soluble antibodies inhibiting TNFα (2023-02-14),

9. 11427628 - Antibody frameworks (2022-08-30),

10. 11421035 - Stable antibody variable domain framework combinations and methods of use thereof (2022-08-23),

11. 11319371 - Anti-CD3 antibodies (2022-05-03),

12. 11236150 - Hetero-dimeric multi-specific antibody format (2022-02-01),

13. 11046757 - Solubility optimization of immunobinders (2021-06-29),

14. 10781268 - Method for decreasing immunogenicity (2020-09-22),

15. 10590193 - Stable and soluble antibodies inhibiting VEGF (2020-03-17),

Title: The Innovative Journey of David M. Urech

Introduction

David M. Urech, a prominent inventor based in Männedorf, Switzerland, has made significant contributions to the field of biomedicine with a remarkable portfolio of 47 patents. His work primarily focuses on advancing antibody technologies, which play a crucial role in therapeutic applications.

Latest Patents

Among Urech's notable inventions is the multispecific antibody that comprises a CD137 binding domain and a PDL1 binding domain. This invention not only encompasses the antibody itself but also includes pharmaceutical compositions and methods for its utilization. Furthermore, Urech's patent on a hetero-dimeric multi-specific antibody format targets both CD3 and human serum albumin (HSA). This innovative format combines multiple antibody variable domains and is designed to enhance therapeutic efficacy.

Career Highlights

David M. Urech has worked with several esteemed companies throughout his career. He has been a part of Esbatech, Alcon Biomedical Research Unit LLC, and Numab Therapeutics AG. His diverse experience across these organizations has played a pivotal role in shaping his expertise and innovative approach in the field of biomedical research.

Collaborations

Throughout his career, Urech has collaborated with notable professionals, including Leonardo Borras and Tea Gunde. These partnerships have likely contributed to the enriching exchange of ideas and accelerated the development of innovative solutions in antibody technologies.

Conclusion

David M. Urech continues to be a leading figure in the field of biomedicine, with his extensive patent portfolio highlighting his commitment to innovation. His groundbreaking work in multispecific antibodies marks a significant advancement in therapeutic methods, promising a brighter future for medical treatments.